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Oncolytic adenoviruses are promising anticancer agents 
due to their ability to self-amplify at the tumor mass. 
However, tumor stroma imposes barriers difficult to over-
come by these agents. Transgene expression is a valuable 
strategy to counteract these limitations and to enhance 
antitumor activity. For this purpose, the genetic back-
bone in which the transgene is inserted should be opti-
mized to render transgene expression  compatible with 
the adenovirus replication cycle and to keep genome 
size within the encapsidation size limit. In order to 
design a potent and selective oncolytic adenovirus that 
keeps intact all the viral functions with minimal increase 
in genome size, we inserted palindromic E2F-binding 
sites into the  endogenous E1A promoter. The insertion of 
these sites controlling E1A-Δ24 results in a low systemic 
toxicity profile in mice. Importantly, the E2F- binding 
sites also increased the cytotoxicity and the systemic 
antitumor activity relative to wild-type adeno virus in all 
cancer models tested. The low toxicity and the increased 
potency results in improved antitumor efficacy after sys-
temic injection and increased survival of mice carrying 
tumors. Furthermore, the constrained genome size of 
this backbone allows an efficient and potent expression 
of transgenes, indicating that this virus holds promise 
for overcoming the limitations of oncolytic adenoviral 
therapy.
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IntroductIon
Despite great advances in the treatment of cancer, it remains one 
of the leading causes of mortality worldwide. Therefore, research 
on novel cancer therapies with a high therapeutic index limited to 
malignant tissues is crucial. Among new treatments proposed to 
target cancer, oncolytic adenoviruses are a promising and appeal-
ing therapy due to their ability to self-amplify selectively at the 
tumor site.1 Several oncolytic adenoviruses have already been 
tested in clinical trials involving a variety of tumors and routes 
of administration. Clinical data revealed a good toxicological and 
safety profile, but some potentially concerning adverse effects 
were observed after administration at high doses.2 With regard 
to efficacy, most responses detected were transient and the treat-
ment was not able to alter significantly the course of the  disease. 
Overall, this data indicate out a critical need for improved onco-
lytic potency to result in sustained therapeutic responses in 
humans.
For an efficient treatment of tumors at an advanced stage, sys-
temic delivery is preferred.3 However, the virus encounters some 
limitations when injected systemically. First of all, it is quickly 
eliminated from the bloodstream by the liver or inactivated by 
binding to blood cells, neutralizing antibodies, or complement,4 
and only a minimal proportion of the injected dose reaches the 
tumor. Once in the tumor, the stroma and the antiviral immune 
response limit the spread of the virus throughout the tumor.5 
The expression of a therapeutic transgene from the adenoviral 
backbone is a rational and efficient approach to circumvent these 
limitations. Armed replicating adenoviruses are a combination 
of virotherapy and gene therapy strategies in which the input of 
transgene dose is amplified by replication of the virus and, above 
all, gene transfer can amplify the antitumor activity of virotherapy. 
In this regard, several transgenes have been inserted into onco-
lytic adenoviruses in order to increase cytotoxicity, to stimulate 
immune responses, or to digest the connective tissue to facilitate 
intratumoral spread.6 However, encapsidation size of the adeno-
virus type 5 is limited to 105% of the wild-type genome, and larger 
genomes result in genetic instability and packaging problems.7 E3 
genes have been deleted to create space for transgenes, but E3 has 
important immune inhibitory functions that may facilitate virus 
spread in immunocompetent hosts.8 Thus, further research is 
needed to optimize the transgene expression machinery and the 
adenoviral backbone in which the transgene is inserted in order to 
minimize genome size and make transgene expression compatible 
with both selective and potent replication.
Taking into consideration the concerning adverse effects 
observed in clinical trials after systemic injection of oncolytic 
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adenoviruses,2 it is important to restrict virus gene expression 
to tumor cells to ensure virus safety. In mice, E1A expression 
in hepatocytes is enough to cause transaminitis and severe liver 
injury,9 and this toxicity is not prevented by deletions in other viral 
genes that confer selectivity. Modification of E1A transcriptional 
control is a useful approach to avoid this toxicity. Tissue-specific 
promoters have been tested in this regard to treat certain types of 
cancer, such as the PSA promoter to target prostate cancer10 or the 
uPAR promoter for pancreatic tumors.11 However, promoters with 
a broader tropism are more appealing due to their  applicability 
to different tumor types. Those active in tumors and repressed in 
normal tissues, such as E2F-1 (ref. 12) or hTERT,13 are an ideal 
option. Nevertheless, some losses of potency with respect to wild-
type transcription control were reported when these promoters 
were placed to control E1A, especially when tested in a wide range 
of cancer models.
In a recent work,14 we demonstrated that the incorporation 
of E2F-responsive palindromes in an insulated E2F-1 promoter 
controlling E1A-Δ24 resulted in increased oncolytic potency 
with a low systemic toxicity profile. The E2F-responsive palin-
dromes boosted a positive feedback loop turned on in cancer 
cells involving E1A and E4-6/7. However, the combination of 
genetic elements present in the resulting oncolytic adenovirus 
(ICOVIR-7) raised its genomic size close to the 105%  packaging 
limit, and this hindered the incorporation of transgenes to 
this highly tumor-selective backbone. In the present study, 
we develo ped a novel oncolytic adenovirus (ICOVIR-15) that 
achieved selective and potent replication in tumor cells with a 
genomic size that only exceeds the native Ad5 size by 151 base 
pairs (bp). Four palindromic E2F-binding sites and one Sp-1-
binding site were inserted in the endogenous E1A promoter to 
redirect E1A-Δ24 transcription toward pRb deregulation. As a 
consequence, viral replication was enhanced compared to Adwt-
RGD in all cancer models tested, and potent antitumor activ-
ity was achieved when injected systemically in tumor models 
in vivo. Toxicity caused in mice by Adwt-RGD and AdΔ24-RGD 
was considerably reduced by this modification and allowed safe 
systemic administration at high doses. Importantly, the reduced 
genome size of ICOVIR-15 improves its suitability for transgene 




The transcription of the E1A gene in wild-type Ad5 is regulated by 
a variety of cellular and viral protein factors.15 The transcriptional 
control region of E1A extends from the left terminus of the virus 
genome to the E1A cap site and contains the replication origin of 
Ad DNA, the inverted terminal repeat, the packaging elements, 
the transcriptional enhancer elements for the E1A gene and other 
viral early genes, and the promoter proximal elements of the E1A 
gene (Figure 1). ICOVIR-15 is a novel AdΔ24-RGD-derivative 
oncolytic adenovirus that incorporates four E2F-responsive pal-
indromes downstream of the packaging signal to redirect E1A 
transcription toward deregulation of the retinoblastoma (Rb/p16) 
pathway. These palindromic-binding sites are responsible for the 
potency and selectivity of the E2F-1 promoter and play a dual role 
controlling transcription in response to E2F status.16 Furthermore, 
one Sp-1-binding site was also inserted as both transcription fac-
tors interact to cooperatively activate transcription.17 Figure 1 
represents schematically the binding sites inserted into the 
E1A promoter and their different role in tumor or normal cells. 
Importantly, this modification preserves the original structure 
of the adenovirus genome and the function of the E1A enhancer 
region, which may contribute to an efficient selective replication 
in the cancer cell without affecting the antitumor potency. The 
insertion of the RGD peptide at the HI-loop of the fiber allows 
CAR-independent target cell infection and increases virus infec-
tivity.18 Moreover, genome sizes of Adwt-RGD and ICOVIR-15 
are also indicated in the figure.
the palindromic e2F-binding sites in IcoVIr-15 
enhance the antitumor activity of Adwt-rGd in vitro 
and in vivo
Due to deregulation of the retinoblastoma (Rb/p16) pathway, E2F 
is ubiquitously released from the E2F–Rb complexes in tumor 
cells.19 The binding of free E2F to E2F-palindromic sites in the 
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Figure 1 schematic diagram of E1A transcriptional control. ICOVIR-15 incorporates eight extra E2F-responsive sites organized in four palin-
dromes. Furthermore, one extra Sp-1-binding site was also inserted. Genetic modifications in ICOVIR-15 increase genome size by only 151 bp. In 
cancer cells, the E2F transcription factor is released from E2F–Rb complexes, due to pRb pathway deregulation. When ICOVIR-15 infects a tumor cell, 
free E2F binds to the E2F-palindrome sites present in the modified E1A promoter and activates E1A-Δ24 transcription. The Sp-1 transcription factor 
cooperates with E2F to activate transcription. E1A proteins activate the transcription of the other early adenoviral proteins, including E4-6/7, which 
forms a complex with free E2F that binds to the palindromic E2F sites inserted in ICOVIR-15 promoter to further activate E1A transcription. The same 
palindromic E2F motif is also present in the E2 promoter, resulting in an efficient loop of autoactivation and lysis of cancer cells. The RGD-modified 
fiber increases virus infectivity. In normal, quiescent cells, functional pRb forms an inhibitory complex with the E2F transcription factor. After infection 
of normal cells, binding of E2F–pRb complexes to the E2F-responsive sites inserted in ICOVIR-15 docks histone deacetylases to the E1A promoter and 
prevents E1A-Δ24 transcription. Whereas the wt E1A protein can release free E2F from the pRb–E2F complexes, the Δ24-deletion in E1A prevents 
this, thereby preventing an autoactivation loop driven by E2F in the event of leaky E1A-Δ24 expression. Adwt-RGD, wild-type adenovirus with RGD-
modified fiber; bp, base pair; HDAC, histone deacetylase; II, enhancer element II; ITR, inverted terminal repeat; RB, retinoblastoma protein.
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the E1A gene. Higher levels of E1A proteins should enhance the 
transactivation of the other adenoviral early proteins, including 
E4-6/7. E4-6/7 protein forms a complex with two E2F transcrip-
tion factors and induces the cooperative and stable binding of 
this complex to the palindromic E2F-binding site structure pres-
ent in the E2 promoter20 and in the E1A promoter of ICOVIR-15, 
activating a positive feedback that should culminate in higher 
 production of virus progeny and lysis of the tumor cell. To confirm 
such hypothesis, a panel of tumor cell lines representing a wide 
range of cancer types was evaluated for the effects of ICOVIR-15 
infection. As shown in Figure 2a, E1A protein levels after infec-



































































































IC50 AdwtRGD: 0.19 ± 0.04
IC50 ICOVIR-15: 0.055 ± 0.01
#
IC50 AdwtRGD: 2.3 ± 0.63
IC50 ICOVIR-15: 0.89 ± 0.14
#
IC50 AdwtRGD: 1.15 ± 0.16
IC50 ICOVIR-15: 0.46 ± 0.05
#
IC50 AdwtRGD: 0.042 ± 0.003
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Figure 2 IcoVIr-15 improves antitumor efficacy compared to Adwt-rGd. (a) The E2F-responsive palindromes enhance the E1A expression 
driven by the endogenous E1A promoter. Anti-E1A western blots were performed 24 hours after infecting cells with a dose of each virus that allowed 
>80% transduction [multiplicity of infection (TU/cell) of 20 for Sk-mel28 and NP-9; 10 TU/cell for A549 cells]. The relative intensities of bands were 
measured by densitometry. AdTL-RGD is a replication-deficient control and Adwt-RGD is a wild-type adenovirus with an RGD-modified fiber. (b) Viral 
production of ICOVIR-15 in tumor cells. Different tumor cell lines were infected as indicated in a or with 20 transduction units (TU)/cell for Isrec-01. 
Virus production was measured 3 days after infection. Viral yield was evaluated in quadruplicate for each cell line, by carrying out two independent 
experiments. (c) Comparative cytotoxicity of ICOVIR-15. Cells were infected with the indicated viruses at doses ranging from 500 to 0.0001 TU/cell. 
IC50 values (TU/cell required to cause a reduction of 50% in cell culture viability) at days 5–8 after infection are shown. Four different replicates were 
quantified for each cell line. Mean ± SD error bars are plotted. (d) Relative tumor growth after systemic injection of Adwt-RGD or ICOVIR-15. Nude 
mice harboring subcutaneous xenografts of Sk-mel28 cells (melanoma) were randomized and injected with a single intravenous dose of 2.5 × 1010 
viral particles per mouse of Adwt-RGD or ICOVIR-15. Phosphate-buffered saline (PBS) administration was used as a control. ICOVIR-15 significantly 
reduced tumor growth compared to Adwt-RGD and PBS from early days in the experiment. Mean values of 16 tumors/group ± SE are depicted. 
#Significant P < 0.05 by two-tailed unpaired Student’s t-test, compared to Adwt-RGD group. *Significant (P < 0.05) by two-tailed unpaired Student’s 
t-test, compared to PBS group. Adwt-RGD, wild-type adenovirus with RGD-modified fiber.
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Figure 3 toxicity profile after systemic injection of IcoVIr-15 in immunocompetent mice. (a) Body weight variation was monitored after intra-
venous administration of 5 × 1010 viral particles per mouse of Adwt-RGD, AdΔ24-RGD, or ICOVIR-15. Phosphate-buffered saline (PBS) administration 
was used in the control group. Adwt-RGD and AdΔ24-RGD-injected mice were killed at day 4 due to lethal toxicity, whereas ICOVIR-15-injected 
mice presented a similar weight profile than those injected with PBS. At 6 hours after administration, capsid-mediated IL-6 elevation was analyzed in 
(b) peripheral blood, meanwhile (c,d) serum transaminases and (e) platelet concentrations were analyzed at 6 hours, day 4 or day 12 after adminis-
tration. Mean values ± SD of 5–10 mice/group are depicted. *Significant (P < 0.05) by two-tailed unpaired Student’s t-test, compared to Adwt-RGD 
group. §Significant (P ≤ 0.05) by two-tailed unpaired Student’s t-test, compared to AdΔ24-RGD group. #Significant (P < 0.05) by two-tailed unpaired 
Student’s t-test, compared to PBS group. Adwt-RGD, wild-type adenovirus with RGD-modified fiber; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; IL-6, interleukin 6.
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the parental virus Adwt-RGD in all cancer cell lines tested when 
analyzed by western blot and quantified by densitometry. E1A 
protein levels from ICOVIR-15 were 1.8, 3.4, and 4 times higher 
in A549, Sk-mel28, and NP-9, respectively, compared to Adwt-
RGD levels.
To determine whether this increase in E1A amounts has a 
positive impact on the antitumoral potency, virus progeny pro-
duction and cytotoxicity assays were performed. Virus progeny 
production was increased significantly for ICOVIR-15 in two out 
of four cancer cell lines tested, showing a trend for improvement 
in the other two (Figure 2b). When cytotoxicity was analyzed at 
days 5–8, the improvement became more evident because more 
than one cycle of replication occurred (Figure 2c). The E2F-
binding sites rendered ICOVIR-15 more cytotoxic because the 
amount of virus required to reduce the cell culture viability by 
50% (IC50) was 3.5 times (P ≤ 0.022), 2.5 times (P ≤ 0.017), 2.5 
times (P ≤ 0.007), and 1.8 times (P ≤ 0.014) lower in Sk-mel28, 
NP-9, Saos-2, and NP-18 cells, respectively, compared to the 
parental virus Adwt-RGD.
Once we had demonstrated the improved oncolytic potency 
of ICOVIR-15 in vitro, we tested whether this benefit is main-
tained in a tumor xenograft model. As disseminated disease is the 
most relevant clinical situation, systemic injection was used. Mice 
bearing Sk-mel28 (melanoma) tumors were injected with a single 
intravenous dose of phosphate-buffered saline (PBS), Adwt-RGD, 
or ICOVIR-15. The virus dose was 2.5 × 1010 viral particles per 
mouse, which is the maximum tolerated dose for systemic injec-
tion of wild-type adenoviruses in immunocompetent and nude 
mice.12 ICOVIR-15 was more efficient at delaying the growth of 
Sk-mel28 subcutaneous tumors in vivo (Figure 2d). At day 37, 
when untreated mice had to be killed due to uncontrolled tumor 
growth, tumor size of Adwt-RGD-treated mice was 1.5-fold larger 
than in those treated with ICOVIR-15 (P < 0.025). Tumor size 
in PBS-treated mice was 1.8-fold larger than in the ICOVIR-15 
group (P < 0.005).
In vivo systemic toxicity after IcoVIr-15 
administration in Balb/c immunocompetent mice
Binding of pRb–E2F–HDAC complexes to E2F sites inserted 
into the E1A promoter should restrict transcription and dimin-
ish E1A-mediated toxicity in normal cells, thus allowing systemic 
administration for the treatment of disseminated neoplasias. The 
toxicity associated to a single intravenous dose of ICOVIR-15 or 
controls was assessed in Balb/C immunocompetent mice. Viruses 
were injected at a dose of 5 × 1010 viral particles per mouse and 
body weight was monitored daily. Adwt-RGD- and AdΔ24-
RGD-injected mice were killed at day 4 after injection due to 
high decrease in body weight and high morbidity. In contrast, 
ICOVIR-15-injected group only suffered a 1% reduction in the 
body weight (not significant) at day 3 after administration and 
underwent a rapid recovery to PBS levels (Figure 3a).
Administration of adenoviruses induces two distinct peaks of 
inflammatory response.21 The early phase, occurring at 6 hours 
after administration, is capsid-mediated and has been associ-
ated with elevation of cytokines such as IL-6 (ref. 22). Adwt-
RGD, AdΔ24-RGD, and ICOVIR-15 share identical capsids, 
and, accordingly, similar IL-6 concentrations in peripheral blood 
were detected 6 hours after systemic administration (Figure 3b). 
Furthermore, as a large proportion of the oncolytic agent ends up 
in the liver after systemic administration, transaminase elevation 
has been reported in clinical trials after injections of high doses.2 
When transaminase enzymes (aspartate aminotransferase and 
alanine aminotransferase) were analyzed 6 hours after admin-
istration, only a slight nonsignificant increase was detected for 
both transaminases (Figure 3c,d). On the other hand, the second 
 toxicity peak is dependent on transcription of viral proteins and 
it occurs at days 4–5 after administration. Up to a 44- and 87-fold 
elevation of aspartate aminotransferase and alanine aminotrans-
ferase, respectively, was detected in Adwt-RGD and AdΔ24-RGD-
treated mice compared with nontreated animals when analyzed at 
day 4 after injection (Figure 3c,d). On the contrary, only a slight, 
transient transaminase elevation was detected in the ICOVIR-15-
injected group. At day 4 after administration, an eightfold eleva-
tion in aspartate aminotransferase (not significant) and a 20-fold 
in alanine aminotransferase (not significant) were detected, but 
these elevations resolved by day 12. Furthermore, liver toxicity 
causes an increment in portal vein hypertension, the sequestra-
















Figure 4 IcoVIr-15 reduces hepatic e1A expression in vivo. (a) Mouse 
livers were collected at day 4 after intravenous administration of PBS or 
viruses, and E1A expression was assessed by immunohistofluorescence 
in frozen sections. E1A was barely detected in livers from mice injected 
with ICOVIR-15, whereas intense detection was observed throughout 
the livers of Adwt-RGD-injected mice. (b) E1A detection correlated with 
evident signs of hepatitis when analyzed by eosin–hematoxylin stain-
ing of paraffin-embedded liver sections. Pathological changes including 
macrosteatosis, presence of Councilman bodies, and large necrotic areas 
were present in livers from mice injected with Adwt-RGD, but not in 
those injected with ICOVIR-15. Adwt-RGD, wild-type adenovirus with 
RGD-modified fiber; PBS, phosphate-buffered saline.
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count.23 Although a serious thrombocytopenia was observed after 
Adwt-RGD or AdΔ24-RGD injection (2.6-fold reduction, P ≤ 
0.002), platelet depletion mediated by ICOVIR-15 was only 1.4-
fold at day 4 and absent at day 12 (Figure 3d).
In addition, E1A expression was evaluated in murine liver 
sections by immunostaining as it is the main cause of toxicity in 
mice.9 Strong E1A staining was detected throughout livers from 
Adwt-RGD- and AdΔ24-RGD-injected mice (Figure 4a). On 
the contrary, little E1A was detected in livers from mice treated 
with ICOVIR-15 and this correlates with a histological analy-
sis of liver sections (Figure 4b). Although evident symptoms of 
degenerative cirrhosis (macrosteatosis, presence of Councilman 
bodies, and large necrotic areas) were detected in livers from the 
Adwt-RGD and AdΔ24-RGD group, livers from ICOVIR-15-
treated mice displayed an almost normal phenotype, with only 
marginal Councilman bodies in the superficial areas. These data 
indicate that the E2F-responsive palindromes inserted to control 
E1A expression are actively repressing transcription in normal 
cells. Once we confirmed that the dose of 5 × 1010 viral particles 
of ICOVIR-15 per mouse was well tolerated, we evaluated the sys-
temic antitumoral activity of this novel oncolytic agent at this dose 
in several tumor xenograft models.
IcoVIr-15 exhibits potent antitumor efficacy and 
prolongs mouse survival after systemic administration
A549 (lung), NP-9 and NP-18 (pancreatic adenocarcinoma), PC-3 
(prostate), and Sk-mel28 (melanoma) were selected as subcutaneous 
models in order to represent a range of tumor types. Mice carrying 
tumors were injected with a single intravenous dose of ICOVIR-15 
at 5 × 1010 viral particles per mouse or PBS. When untreated animals 
displayed uncontrolled tumor growth, mice were killed. At killing, 
ICOVIR-15 treatment induced a reduction of more than 3.7-fold 
(P < 0.0012), threefold (P < 0.012), 2.3-fold (P < 0.00007), 2.8-fold 
(P < 0.0001), and 1.7-fold (P < 0.03) in the tumor size of NP-18, 
A459, Sk-mel28, NP-9, and PC-3 subcutaneous tumors, respec-
tively (Figure 5a). Importantly, efficient tumor growth reduction 
was achieved in all subcutaneous tumor models tested. In addition, 
ICOVIR-15 treatment was able to significantly increase survival in 
all subcutaneous tumor models tested (Figure 5b).
the reduced genome size of IcoVIr-15 allows potent 
transgene expression without affecting viral kinetics
Late-phase expression of transgenes that promote viral spread or 
have cytotoxic effects may improve the ability of oncolytic aden-
ovirus to eradicate tumors.1 It is preferable to restrict transgene 
expression to the late phase of the virus replication cycle in order 
to minimize any antagonism between transgene activity and virus 
replication.24 However, the ability of Ad5 to carry exogenous DNA 
is limited by its encapsidation capacity, which is ~38 kilobases.7 To 
determine whether the ICOVIR-15 backbone could be compat-
ible with late transgene expression, we cloned the NfsA nitrore-
ductase gene downstream of the fiber (Figure 6a). Escherichia coli 
nitroreductases, such as NfsA or NfsB, are flavoenzymes that 
can catalyze the reduction of nitro groups in a wide range of 
substrates, and they have been identified as useful in the meta-
bolism of a number of prodrugs in anticancer gene therapy.25 The 
NfsA gene cloned included the 3VDE splicing acceptor (IIIa virus 
infection–dependent splicing enhancer) and a polyA sequence in 
order to promote its expression during the late phase of the viral 
life cycle.
To establish whether the insertion of NfsA alters virus rep-
lication, we compared virus progeny production and release of 
ICOVIR-15 and ICOVIR-15-NfsA. A549 cells were infected at 
high multiplicity of infection, and the amount of virus produced 
and released was determined at different time points. As shown 
in Figure 6b, the production and release kinetics of both viruses 
were similar at every time point, indicating that the transgene is 
not reducing the oncolytic potency of ICOVIR-15. Furthermore, 
the timing of nitroreductase expression was evaluated by  western 
blot analysis to confirm late-phase expression. As shown in 
Figure 6c, NfsA was undetectable 24 hours after infection, its 
expression was slightly detected at 48 hours, and high amounts of 
transgene accumulated 72 hours after infection. To determine the 
functionality of NfsA, a cytotoxicity assay was performed in FaDu 
cells with or without CB1954 prodrug. When CB1954 was not 
present in the media, the amount of ICOVIR-15-NfsA required 
to reduce the cell culture viability by 50% (IC50) was similar to 
that of ICOVIR-15 (Figure 6d). On the contrary, when a dose of 
100 μmol/l of CB1954 was added to the media, ICOVIR-15-NfsA 
IC50 was reduced five times (P ≤ 0.014) compared with ICOVIR-15, 
indicating that NfsA is reducing CB1954 to toxic metabolites with 
bystander effect.
In summary, these results indicate that the new E2F-binding 
sites introduced into the E1A promoter in ICOVIR-15 are able to 
increase the antitumor potency of the wild-type adenovirus while 
drastically reducing toxicity after systemic injection. Moreover, its 
constrained genome size permits the insertion of transgenes with-
out affecting the oncolytic potency.
dIscussIon
Oncolytic adenoviruses have proven efficacious and relatively safe 
in the clinics.2 However, clinical response rates are suboptimal, and 
further research is needed to improve the antitumor potency of 
these agents. One of the main limitations for efficacy is the inabil-
ity of oncolytic adenoviruses to spread sufficiently within solid 
tumors.5 Some strategies aiming to increase adenovirus spread 
include mutations in E1B-19K,26 overexpression of the adenovirus 
death protein,27 or c-terminal truncating mutations in the i-leader 
protein.28 However, several side effects such as virus yield reduc-
tion29 or partial loss of the E3 immunomodulatory functions30 have 
been reported with these approaches. An alternative strategy aim-
ing to increase virus spread within the tumor mass is the expression 
of transgenes from the adenovirus backbone, such as proteases to 
disrupt the extracellular matrix5 or enzymes that convert prodrugs 
to diffusible cytotoxins that provide bystander killing of surround-
ing cells.31 However, the insertion of transgenes into the adenovirus 
genome is limited by the encapsidation size and requires transgene 
compatibility with the adenovirus replication cycle.
For an effective therapy, systemic delivery of the oncolytic 
agent is preferred in the clinical setting as patients may have inac-
cessible tumors or tumors that are already metastatic at the time 
of detection.3 Our group has previously described ICOVIR-7, an 
oncolytic adenovirus showing antitumor efficacy in a wide range 
of subcutaneous tumor models after systemic administration, with 
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a low toxicity profile.14 ICOVIR-7 controls the transcription of the 
E1A-Δ24 protein via an improved E2F-1 promoter insulated with 
the myotonic dystrophy locus insulator. It also contains an RGD-
modified fiber to increase virus infectivity. Due to the benefits that 
the expression of certain transgenes may grant in terms of onco-
lytic potency, we considered arming this virus. However, the com-
bination of all the genetic elements present in ICOVIR-7 raised 
its genome size to 37,053 bp, close to the 105% packaging limit,7 
and when we attempted to introduce transgenes into this back-
bone, it resulted in genome instability and packaging problems 
(data not shown). As a measure to gain DNA insertion capacity, 
we deleted ORF 1 and 2, or ORF 1, 2, and 3 of the adenovirus 
E4 region. Although no important functions in replication have 
been associated with these proteins,32 the resulting viruses showed 
significant loss of potency and replication defects in cancer cells 
compared with their controls (S. Guedan, unpublished results). 
Thus, we sought a novel modification that restricted a potent 
E1A transcription to cancer cells with only minimal increase in 
genome size, in order to retain the potential for efficient delivery 
and expression of additional transgenes.
Deregulation of the retinoblastoma (Rb/p16) pathway is a 
hallmark of tumor cells.33 As a consequence of Rb pathway defects, 
E2F transcription factors are released, allowing activation of pro-
moters containing E2F sites. Furthermore, the same E2F-binding 
sites can mediate silencing of these promoters in quiescent cells 
due to the formation of a complex involving E2F–pRb complexes 
and histone deacetylases.34 An oncolytic adenovirus that con-
trols E1A transcription by E2F sites may acquire potent, tumor-
selective replication in a wide range of cancer cells. Importantly, 
a palindromic E2F-binding site pattern was described to perform 
an important role in adenovirus life cycle: the E4-6/7 protein 
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Figure 5 efficacy and survival after systemic administration of IcoVIr-15. (a) Nude mice bearing subcutaneous xenografts of lung (A549), 
 prostate (PC-3), pancreatic carcinoma (NP-9 and NP-18), or melanoma (Sk-mel28) were injected with a single intravenous dose of phosphate-
buffered saline (PBS) or 5 × 1010 viral particles (vp) per mouse of ICOVIR-15. Relative tumor volume (percentages of size at treatment, mean ± SE) of 
12–18 tumors/group are plotted. #Significant P < 0.05 by two-tailed unpaired Student’s t-test compared with mice injected with PBS. (b) Kaplan–
Meier survival curves after administration of a single intravenous dose of PBS or 5 × 1010 vp per mouse of ICOVIR-15. The end point was established 
at a tumor volume of ≥500 mm3. #Significant P < 0.05 by log-rank test compared with mice injected with PBS. PBS, phosphate-buffered saline.
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the cooperative and stable binding of E2F to this palindromic 
pattern to activate transcription.20 This pattern is present in the 
E2F-1 cellular promoter16 as S-phase induction is a requisite for 
the adenoviral life cycle. Moreover, this pattern is also present in 
the adenovirus type 5 E2A promoter to boost its transcription in 
response to E1A and E4 activation.35 The presence of this pattern 
in the adenoviral genome suggests an optimal structure in terms 
of DNA length to confer efficient E2F-responsiveness. Thus, we 
decided to construct a novel oncolytic adenovirus that contained 
palindromic E2F-binding sites in the E1A promoter. ICOVIR-15 
incorporates eight new E2F-binding sites organized as four imper-
fect palindromes downstream of the packaging signal (Figure 1). 
Downstream of these palindromic sites, we also inserted one 
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Figure 6 IcoVIr-15 is able to efficiently express transgenes. (a) Schematic representation of the genetic components present in ICOVIR-15 and 
ICOVIR-15-NfsA. To drive NfsA expression in ICOVIR-15-NfsA from the MLP, the Ad5 IIIa protein splice acceptor (3VDE) was inserted in front of the 
NfsA cDNA, followed by a polyA sequence (pA). These three elements were inserted downstream of the fiber-RGD in the ICOVIR-15 genome. The 
total lengths of both genomes are depicted in the figure. (b) Virus yield and release after infection with ICOVIR-15 and ICOVIR-15-NfsA. Confluent 
A549 cells were infected with 10 transduction units (TU)/cell. Four hours after infection, the viral solution was removed, and cell cultures were washed 
thrice with PBS and incubated with 1 ml of fresh virus-free medium. Cell extracts and supernatants were harvested 4, 12, 24, 48, and 72 hours after 
infection and titrated by an antihexon staining–based method. Viral yield and release were evaluated in quadruplicate. Mean ± SD error bars are 
plotted. (c) Transgene expression driven by ICOVIR-15-NfsA. Anti-NfsA western blots were performed at the indicated time points after infection of 
PC-3 cells at a multiplicity of infection that allowed high transduction. β-Tubulin staining was used as loading control. (d) Comparative cytotoxicity 
of ICOVIR-15 and ICOVIR-15-NfsA in FaDu cells with and without CB1954 prodrug. FaDu cells were infected with the indicated viruses at doses rang-
ing from 100 to 0.001 TU/cell. CB1954 was added at 100 µmol/l to demonstrate NfsA activity. IC50 values (TU/cell required to cause a reduction of 
50% in cell culture viability) at day 6 after infection are shown. Four different replicates were quantified for each cell line. Mean ± SD error bars are 
plotted. #Significant P ≤ 0.02 by two-tailed unpaired Student’s t-test compared with ICOVIR-15 plus CB1954 at 100 µmol/l. 3VDE, IIIa virus infection–
dependent splicing enhancer; CB1954, 5-(1-Aziridinyl)-2,4-dinitrobenzamide, 5-(Aziridin-1-yl)-2,4-dinitrobenzamide; CE, cell extract; MLP, major late 
promoter; pA, polyA sequence; SN, supernatant; TU, transduction units.
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in the E2F-controlled promoters by interacting and cooperating 
to activate transcription.17 Contrary to an insulated exogenous 
promoter, this modification preserves the function of the element 
II in the E1A enhancer, which was previously reported to activate 
transcription of all of the early promoters in cis.36 Moreover, as 
a measure to prevent an autoactivation loop by E2F in the case 
of promoter leakage, the pRb-binding site of E1A was deleted 
(Δ24 deletion).37 An RGD motif was also inserted at the HI-loop 
of the fiber to increase virus infectivity to cancer cells.18
Taking into consideration that the mouse is not permissive for 
human adenovirus replication, the main toxicity in mice is asso-
ciated with E1A expression.9 The palindromic E2F-binding sites 
present in ICOVIR-15 may repress E1A transcription in quiescent 
cells due to binding of E2F–pRb–histone deacetylase complexes, 
which strengthen the association of nucleosomes with DNA.34 
The systemic administration of Adwt-RGD or AdΔ24-RGD at a 
dose of 5 × 1010 viral particles per mouse caused an increase in 
transaminases levels, degeneration of liver tissue, hematological 
alterations, and severe weight loss (Figures 3 and 4). In fact, this 
dose represents more than the LD50 value in immunocompetent 
mice for adenoviruses controlling E1A under the wild-type pro-
moter.12 In contrast, the injection of ICOVIR-15 at the same dose 
only caused slight alterations in transaminases levels and in plate-
let concentration at day 4 (Figure 3). This toxicity was transient 
and a complete recovery was achieved 12 days after the treatment. 
Thus, we can conclude that the insertion of palindromic E2F sites 
drastically reduces the toxicity following systemic administration 
of wild-type human adenovirus to mice.
Furthermore, our results demonstrate that the novel palindro-
mic E2F-binding sites enhance the antitumor activity compared 
to wild-type human adenovirus. In contrast to some reports in 
which reduced E1A expression had little effect on replication,38,39 
an increased level of E1A led to an improved viral yield, and this 
resulted in improved cytotoxicity in a variety of cell types includ-
ing melanoma, osteosarcoma, and pancreatic adenocarcinomas 
(Figure 2a–c). Importantly, oncolytic potency improved in all 
tumor cell lines tested, in contrast to our previously described 
viruses where the presence of an insulated E1A promoter may 
limit the capacity of E1A enhancers to activate the other viral 
proteins.12,14 The benefit of ICOVIR-15 in terms of oncolytic 
potency was confirmed in vivo, where a single intravenous injec-
tion significantly increased the tumor growth inhibition relative 
to Adwt-RGD (Figure 2d). This experiment was performed at the 
maximum tolerated dose for Adwt-RGD by systemic injection 
in immunocompetent and nude mice. As ICOVIR-15 has lower 
toxicity than this nonselective virus and allows systemic injection 
at higher doses, the antitumor activity of a dose of 5 × 1010 viral 
 particles per mouse was tested in a wide range of subcutaneous 
xenograft tumors, including melanoma, prostate, lung and pan-
creatic adenocarcinoma. A substantial benefit in the control of 
tumor growth and a significant increase in survival were observed 
compared to nontreated animals (Figure 5), suggesting an impor-
tant antitumor activity of ICOVIR-15 when injected systemically.
As previously reported,40 a histology analysis of tumors after 
adenovirus administration revealed that the presence of tumor 
stroma limits the complete intratumoral spread of the oncolytic 
agent (data not shown). This was especially noteworthy in the 
PC-3 xenograft model, which expresses high amounts of matrix 
components.41 The expression of transgenes that contribute to 
disruption of the stromal barriers, such as proteolytic enzymes to 
degrade the matrix components42 or prodrug-converting enzymes 
to kill fibroblasts,31 may be used to enhance the viral spread within 
the tumor. Importantly, ICOVIR-15 has a similar genome size to 
wild-type adenovirus (only 150 bp more), which may facilitate 
the incorporation of transgenes. In order to evaluate whether 
the insertion of a transgene has negative effects on ICOVIR-15 
replication, we constructed an armed version that incorporates 
an expression cassette of the transgene NfsA. NfsA is the major 
Escherichia coli nitroreductase and it can activate a variety of 
nitroaromatic prodrugs for cancer gene therapy.25 The replication, 
the release, and the cytotoxicity of ICOVIR-15-NfsA were indis-
tinguishable from those of its unarmed control (Figure 6b,c), 
indicating the suitability of ICOVIR-15 for delivering additional 
transgenes. Furthermore, NfsA expressed from ICOVIR-15 back-
bone was active as it minimized the amount of virus necessary 
to cause a reduction of 50% in tumor cell culture viability after 
adding CB1954 prodrug to the media (Figure 6c). To maintain 
tumor- selective expression of the transgene, we inserted addi-
tional splicing signals within the major late transcription unit. 
This strategy confers E1A-dependent transcription and achieves 
efficient, regulated transgene expression with a small DNA 
sequence. The 3VDE sequence (IIIa virus infection–dependent 
splicing enhancer) from the adenoviral IIIa protein is a useful 
splicing signal for late transgene expression because it is subject to 
a strict regulation during virus infection.43 As shown in Figure 6c, 
the expression of NfsA driven by the 3VDE sequence in ICOVIR-
15-NfsA was strictly restricted to the late phase of the viral cycle.
In addition to transgenes that enhance cytotoxicity or adeno-
viral distribution within the tumor, other transgenes may enhance 
the antitumor activity of ICOVIR-15. The expression of transgenes 
that modulate the tumor microenvironment, such as murine 
endostatin to inhibit the process of angiogenesis or TIMP3 to 
inhibit the action of matrix metalloproteinases, may improve the 
oncolysis by hindering tumor development.44,45 Furthermore, the 
expression of fusogenic proteins, such as GALV protein, may also 
enhance antitumor activity by syncytium formation.43 On the other 
hand, a different strategy is the expression of factors that recruit 
immune cells to the site of infection and induce their proliferation 
and activation. This strategy has the potential to destroy not only 
the primary tumor, but also remote metastases. Cytokines, such 
as GM-CSF or MCP-3, or interleukins, such as IL-4 or IL-24, have 
been used previously to arm oncolytic adenoviruses.6 All these 
strategies would confer different characteristics to ICOVIR-15 
and warrant testing as candidates for clinical trials.
In summary, our results indicate that ICOVIR-15 displays 
an appealing efficacy to toxicity ratio. On one hand, the inserted 
 palindromic E2F-binding sites reduce the toxicity caused by 
 systemic injection of adenoviruses. On the other hand, the same 
binding sites enhance the oncolytic potency even when compared 
to the nonselective wild-type adenovirus, which is particularly 
noteworthy due to the requirements of enhanced potency in the 
clinics. Importantly, the broad spectrum and the small genome size 
of this novel oncolytic adenovirus represent an optimal backbone to 
insert transgenes without deleting viral functions, which may help 
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to overcome the barriers imposed by the complex architecture of 
tumors.
MAterIAls And Methods
Cell culture. HEK293 (human embryonic kidney cells), A549 (human 
lung adenocarcinoma), Sk-mel28 (melanoma), PC-3 (prostate adenocar-
cinoma), Saos-2 (osteosarcoma), and FaDu (squamous cell carcinoma) 
cell lines were obtained from the American Type Culture Collection 
(Manassas, VA). NP-9 and NP-18 (pancreatic adenocarcinomas) cell lines 
were established in our laboratory.46 Isrec-01 (colon cancer cell line) was a 
kind gift from R. Iggo (Institut Bergonié, Bordeaux, France). All tumor cell 
lines, excluding Isrec-01, were maintained in Dulbecco’s modified Eagle’s 
medium containing 5% fetal bovine serum at 37 °C, 5% CO2. Isrec-01 cells’ 
Dulbecco’s modified Eagle’s medium was supplemented with 10% fetal 
bovine serum.
Viruses. Adwt-RGD, AdΔ24-RGD, and AdTL-RGD have been previ-
ously described.18,47,48 Adwt-RGD was propagated in A549 cells, and the 
replication-deficient AdTL-RGD and Ad-CMV-NfsA were propagated 
in HEK293 cells. ICOVIR-15 was created by inserting four E2F-binding 
site hairpins and one Sp-1-binding site following nucleotid 415 in the E1a 
promoter of AdΔ24-RGD.47 To achieve this, a unique BsiWI site was cre-
ated by site-directed mutagenesis in the adenoviral shuttle vector pEndK/
SpeI. An Sp-1 site was introduced using this plasmid digested with BsiWI 
and the annealed oligonucleotides Sp1F (5′-GTACGTCGACCACAAAC
CCCGCCCAGCGTCTTGTCATTGGCGTCGACGCT-3′) and Sp1R (5′-
GTACAGCGTCGACGCCAATGACAAGACGCTGGGCGGGGTTTGT
GGTCGAC-3′). E2F hairpins were introduced using the annealed oligo-
nucleotides E2FF2 (5′-GTACGTCGGCGGCTCGTGGCTCTTTCGCG
GCAAAAAGGATTTGGCGCGTAAAAGTGGTTCGAA-3′) and E2FR2 
(5′-GTACTTCGAACCACTTTTACGCGCCAAATCCTTTTTGCCGCG
AAAGAGCCACGAGCCGCCGAC-3′) to create pEndKBsi415Sp1E2F2. 
For homologous recombination in yeast, the yeast replication elements 
and a selectable marker (CAU fragment49) were cloned into this vector. 
The pEndKBsi415Sp1E2F2CAU linearized with KpnI was recombined 
with AdΔ24-RGD genomic DNA in Saccharomyces cerevisiae YPH857 
to construct pICOVIR-15. ICOVIR-15 was obtained by transfection into 
HEK293 cells of the large PacI fragment of pICOVIR-15. ICOVIR-15-
NfsA was constructed taking advantage of an SpeI site present in pAdwt-
GALV-CAU, a replication-competent adenovirus previously described by 
us.43 By homologous recombination in yeast, the E2F and Sp-1 sites, as well 
as the Δ24 mutation, were introduced. To clone the NfsA gene downstream 
of the fiber protein, plasmid pPS1374J1 was created by amplifying the 
NfsA from the pSV035 plasmid25 using oligonucleotides 5′-CGTCAATT
GTACTAAGCGGTGATGTTTCTGATCAGCCACCATGACGCCAACC
ATTG-3′ and 5′-CAGCAATTGAAAAATAAAGTTTATTAGCGCGTCG 
CCCAACCCTG-3′ and cloning the MfeI-digested PCR product into the 
MfeI site of pNK-FiberRGD.43,50 The pICOVIR-15-NfsA plasmid, con-
taining the complete ICOVIR-15-NfsA genome, was created by homolo-
gous recombination in yeast between pPS1374J1, digested with KpnI 
and NotI, and the pAdwt-GALV-CAU with E2F and Sp-1 sites, digested 
with SpeI. ICOVIR-15-NfsA was obtained by transfection in HEK293 
cells of the PacI fragment of pICOVIR-15-NfsA. Viruses were plaque-
purified, amplified in A549 cells and purified using a CsCl gradient. 
Viral genomes were verified by restriction analysis and by sequencing 
E1A promoter, E1A-Δ24, RGD-modified fiber, and nitroreductase NfsA 
using oligonucleotides oligo22 (5′-AAGTGTGATGTTGCAAGTGT-3′), 
Ad670F (5′-ATCTTCCACCTCCTAGCCAT-3′), FiberUp (5′-CAAACGC 
TGTTGGATTTATG-3′), and FiberDown2 (5′-GGCTATACTACTGAA 
TGAA-3′).
Protein expression analysis. Cell cultures seeded in 24-well plates were 
infected at a multiplicity of infection that allowed at least 80% infectiv-
ity [20 transduction units (TU)/cell for Sk-mel28, NP-9, and PC-3, and 
1010 TU/cell for A549 cells]. Whole-cell protein extracts were prepared at 
the indicated time after infection by incubation in lysis buffer (400 mmol/l 
NaCl, 1 mmol/l EDTA, 5 mmol/l NaF, 10% glycerol, 1 mmol/l sodium 
orthovanadate, 0.5% Nonidet NP-40, and a mixture of protease inhibitors 
(Sigma-Aldrich, St Louis, MO) in 10 mmol/l Tris-HCl pH 7.4) for 1 hour 
at 4 °C. Clarified samples (15 µg/lane) were separated by a 10% SDS–
PAGE gel and transferred to a nitrocellulose membrane (GE Healthcare, 
Arlington Heights, IL). For E1A protein, detection was performed by 
immunoblotting membranes using a polyclonal anti-E1A primary anti-
body (Rabbit, Clone 13S-5) (Santa Cruz Biotechnology, Santa Cruz, CA) 
and a polyclonal anti-rabbit conjugated with horseradish peroxidase (Goat; 
DakoCytomation, Carpinteria, CA). E1A bands from western blot were 
quantified using Bio-Rad GS-800 densitometer (Bio-Rad, Hercules, CA) 
and normalized using unspecific bands detected by the anti-E1A primary 
antibody. For NfsA detection, membranes were immunoblotted using a 
sheep anti-NfsA serum obtained from Alta Bioscience (Birmingham, UK), 
using purified NfsA protein kindly provided by E. Hyde and D. Jarrom 
(School of Biosciences, University of Birmingham, Birmingham, UK), and 
peroxidase-conjugated donkey anti-sheep secondary antibody (Sigma-
Aldrich). A mouse monoclonal anti-β-tubulin antibody and a peroxidase-
conjugated anti-mouse antibody (Goat; Sigma-Aldrich) were used for 
immunoblotting of β-tubulin as a loading control.
Virus release and production assays. Cell cultures (~2 × 105 cells seeded 
in 24-well plates) were infected at a multiplicity of infection that allowed 
at least 80% infectivity (20 TU/cell for Sk-mel28, NP-9, and Isrec-01, 
and 10 TU/cell for A549 cells). Four hours after infection, cultures were 
washed thrice with PBS and incubated in fresh virus-free medium. At the 
indicated time points after infection, a small fraction of the supernatant 
was collected, and the cells and the medium were harvested and frozen-
thawed three times to obtain the cell extract. Viral titers were determined 
by an antihexon staining–based method.12
In vitro cytotoxicity assays. Cytotoxity assay was performed by seeding 
20,000 NP-18 cells, 15,000 Saos-2, FaDu or NP-9 cells, or 10,000 Sk-mel28 
per well in 96-well plates in Dulbecco’s modified Eagle’s medium with 
5% fetal bovine serum. Cells were infected with serial dilutions starting 
with 800 TU/cell for NP-9 cells, 150 TU/cell for NP-18 or Saos-2 cells, or 
100 TU/cell for Sk-mel28 or FaDu cells. For the nitroreductase  activity 
assay, CB1954 (5-(1-Aziridinyl)-2,4-dinitrobenzamide, 5-(Aziridin-1-
yl)-2,4-dinitrobenzamide, Sigma-Aldrich) at 100 μmol/l was added to 
the media at day 0. At days 5–8 after infection, plates were washed with 
PBS and stained for total protein content (bicinchoninic acid assay; Pierce 
Biotechnology, Rockford, IL). Absorbance was quantified, and the TU per 
cell required to produce 50% inhibition (IC50 value) was estimated from 
dose–response curves by standard nonlinear regression (GraFit; Erithacus 
Software, Horley, UK), using an adapted Hill equation.
In vivo toxicity study. Mice for toxicology and efficacy studies were 
maintained in the facility of the Institut de Recerca Oncològica-IDIBELL 
(Barcelona, Spain), AAALAC unit 1155. All animal studies have been 
approved by the Institut d’Investigacio Biomedica de Bellvitge Ethical 
Committee for Animal Experimentation. 5 × 1010 purified viral particles 
were injected intravenously into the tail vein in 6-week-old immunocom-
petent Balb/C male mice in a volume of 10 ml/kg in PBS (n = 5). Daily 
observations for body weight, morbidity, and moribundity were  performed. 
At 6 hours, day 4 or day 12 after injection, mice were killed, and differ-
ent samples were collected. Blood samples were collected by intracardiac 
puncture, and clinical biochemical and hematological determinations 
were performed by the Clinical Biochemistry and Hematological Services 
of the Veterinary Faculty at the Autonomous University of Barcelona. For 
IL-6 determination, we used a Basic Kit Mouse FlowCytomix comple-
mented with Mouse IL-6 FlowCytomix (Bender MedSystems, Vienna, 
Austria), following manufacturer’s instructions. The significance of differ-
ences in biochemical and hematological rates between treatment groups 
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was assessed by a two-tailed Student’s unpaired t-test. Mice livers were 
resected and portions were fixed in 4% formaldehyde for 24 hours at room 
 temperature (for paraffin embedding and further hematoxylin/eosin stain-
ing) or frozen in OCT (Sakura Finetek, Zoeterwoude, the Netherlands). 
E1A-immunodetection was performed by incubating OCT-embedded 
liver sections with a primary polyclonal antibody antiadenovirus-2 E1A 
(clone 13 S-5; Santa Cruz Biotechnology) and an AlexaFluor 488–labeled 
goat anti-rabbit antibody (Molecular Probes, Eugene, OR). Slides were 
counterstained with 4′,6-diamino-2-phenylindole and visualized under 
a fluorescent microscope (Olympus BX51; Olympus Optical, Hamburg, 
Germany).
In vivo antitumoral efficacy. Subcutaneous A549, Sk-mel28, NP-9, 
NP-18, or PC-3 carcinoma tumors were established by injection of 1 × 107 
cells into the flanks of 6-week-old male Balb/C nu/nu mice. When tumors 
reached 100 mm3 (experimental day 0), mice were randomized (n = 
10–16 per group) and were injected by a single intravenous injection of 
PBS, 2.5 × 1010 viral particles of Adwt-RGD or ICOVIR-15, or 5 × 1010 
viral particles of ICOVIR-15 in a volume of 10 ml/kg in PBS via the tail 
vein. Tumor size and mice status were monitored thrice per week. Tumor 
volume was defined by the equation V (mm3) = π/6 × W2 × L, where W 
and L are the width and the length of the tumor, respectively. Data are 
expressed as relative tumor size at the beginning of the therapy, which was 
set as 100%. The significance of differences in relative tumor size between 
treatment groups was assessed by a two-tailed Student’s unpaired t-test. 
For Kaplan–Meier survival curves, end point was established at ≥500 mm3. 
The survival curves obtained were compared for the different treatments. 
Animals whose tumor size never achieved the threshold were included 
as right censored information. A log-rank test was used to determine the 
 statistical significance of the differences in time-to-event.
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